Antengene：Announces Exclusive License Agreement with K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
On June 22, Antengene announced that it has entered into an exclusive license agreement with K2 Therapeutics for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) in development for solid tumors. The company also granted K2 an option to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate .
Under the License Agreement, Antengene is entitled to upfront and near-term considerations of approximately USD 20 million for ATG-106, consisting of cash and a minority equity stake in a newly established asset company and subsidiary of K2 Therapeutics. Antengene is also eligible to receive developmental, regulatory and sales milestone payments of up to USD 960.5 million, plus tiered royalties on future net sales .
Under the Option Agreement, upon exercise of the option, Antengene is entitled to receive approximately USD 20 million in upfront and near-term considerations (including an option exercise fee, near-term payment, upfront payment, and a minority equity stake in the related asset company). Antengene would also be eligible to receive milestone payments of up to USD 960.5 million for the undisclosed TCE program, plus tiered royalties on future net sales .
Both ATG-106 and the undisclosed program leverage Antengene’s proprietary AnTenGager® platform, which offers a differentiated TCE approach. The platform features steric hindrance-based masking of the CD3 binding arm in the absence of target antigen binding, designed to provide potent activity while improving tolerability . This marks the second transaction involving an AnTenGager® TCE, following the global exclusive license agreement with UCB for ATG-201 (CD19 x CD3 TCE) announced in March 2026 .
K2 Therapeutics, established by MPM BioImpact, is a biotech company and scalable hub-and-spoke engine built for global impact, with search and development capabilities unconstrained by modality or geography . K2’s rights under both agreements extend globally, excluding Greater China .
Buy ATG-106 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
